Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Alx Oncology Holdings (ALXO) EBITDA (2019 - 2026)

Alx Oncology Holdings' EBITDA history spans 5 years, with the latest figure at $88.5 million for Q4 2023.

  • On a quarterly basis, EBITDA rose 27.69% to $88.5 million in Q4 2023 year-over-year; TTM through Dec 2023 was -$33.8 million, a 35.19% decrease, with the full-year FY2025 number at -$21.4 million, up 85.01% from a year prior.
  • EBITDA hit $88.5 million in Q4 2023 for Alx Oncology Holdings, up from -$53.3 million in the prior quarter.
  • Over the last five years, EBITDA for ALXO hit a ceiling of $88.5 million in Q4 2023 and a floor of -$53.3 million in Q3 2023.
  • Historically, EBITDA has averaged -$8.0 million across 5 years, with a median of -$14.2 million in 2021.
  • Biggest five-year swings in EBITDA: crashed 274.86% in 2021 and later surged 343.39% in 2022.
  • Tracing ALXO's EBITDA over 5 years: stood at $7.4 million in 2019, then surged by 119.57% to $16.3 million in 2020, then crashed by 274.86% to -$28.5 million in 2021, then surged by 343.39% to $69.3 million in 2022, then rose by 27.69% to $88.5 million in 2023.
  • Business Quant data shows EBITDA for ALXO at $88.5 million in Q4 2023, -$53.3 million in Q3 2023, and -$36.8 million in Q2 2023.